Veraxa Biotech Holding AG Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
European Molecular Biology Laboratory reports beneficial ownership of 22,891,235 ordinary shares, representing 16.2% of Veraxa Biotech Holding AG, following a business combination.
NASDAQ
David Lukas Deck has filed a Schedule 13D, revealing beneficial ownership of 25,502,836 ordinary shares, representing 18% of Veraxa Biotech Holding AG, acquired through a business combination.
NASDAQ
Xlife Sciences AG has filed a Schedule 13D, reporting beneficial ownership of 23,029,967 ordinary shares, representing 16.3% of Veraxa Biotech Holding AG, acquired through a business combination.
NASDAQ
Gilbert Edgar Schoeni has reported beneficial ownership of 22,539,749 ordinary shares, representing 15.9% of Veraxa Biotech Holding AG, following a business combination.